Calculated and fast-thinking practitioner whom top companies are eager to have on side.
IAM Patent 1000
Peter’s practice is focused on patent litigation, with an emphasis on the pharmaceutical, biotech and medical devices sector. In addition to his patent work, Peter has substantial experience in advertising, database, and pharmaceutical regulatory law. Most of Peter’s cases have a multi-jurisdictional dimension, and he is well versed in the litigation strategies and constraints this brings about.
Before specializing in patent law, Peter worked as a corporate lawyer in the M&A department of one of the Netherlands leading full service firms. This background provides him with a good understanding of the commercial and transaction interests of his clients. Peter joined the partnership in 2017.
- Centocor (Johnson & Johnson) v Bayer (2009 to 2012). Successfully defended Centocor against allegations of patent infringement in respect of a patent directed to monoclonal antibodies to human TNF-alpha. The case relates to dealings in Simponi®.
- Janssen Pharmaceutica v Teva (2009-date). Ongoing patent infringement action relating to the beta-blocker Nebivolol®. Chiral chemistry plays an important role in this case Mr Dack’s team takes care of the European coordination of the case.
- Abbott v Medinol (2009-date). Successfully defended Abbott against a patent infringement suit brought by Medinol concerning patents on medical devices (coronary stents). The case concerned Abbott’s Multi-Link® family of stents.
- LifeScan v Roche (2010). Successfully acted for LifeScan in a technical comparative advertising case brought by Roche in respect of medical devices (OneTouch® blood glucose meters).
- Representing the patent holders in infringement proceedings relating to the use of antibody phage display for the manufacture and selection of antibody DNA (2010 to date).
- AGA v Occlutech (2011-date). Representing AGA in its ongoing battle against Occlutech’s copy-cat cardiac implants (ASD/PFO occluders).
- Sanofi v Teva (irebesartan / HCTZ combination SPC) (2012). Successfully obtained, in September 2012, a preliminary injunction and recall order against a manufacturer of a generic version of Sanofi’s CoAprovel product, which is used for the treatment of hypertension. This was the first case in The Netherlands involving the infringement of a combination Supplementary Protection Certificate (SPC) following the decision of the Court of Justice in the Medeva case. The main proceedings are ongoing.
- Member of AIPPI
- Regular speaker on patent litigation related matters
WHAT OTHERS SAY
- “Calculated and fast-thinking practitioner whom top companies are eager to have on side.” IAM Patent 1000 2020
- “He impressed.” Legal 500 2020
- “Very visible in pharma cases.” JUVE Patent 1000 2020
University of Leiden (LLM, cum laude, 2007)